Lifesaving drugs caught up in ‘funding logjam’

Lifesaving drugs have been caught up in a funding logjam as the HSE fears the cost involved could adversely affect existing services.

Nine new hi-tech drugs were recommended for approval by the HSE, subject to additional funding being provided.

The drugs include new treatments for cancer and heart conditions. The HSE confirmed the cost over five years would be around €117m.